Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

January 1, 2021

Study Completion Date

January 1, 2021

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Pegzilarginase

Administered IV

DRUG

Pembrolizumab

Administered IV

Trial Locations (22)

15232

UPMC Cancer Center, Pittsburgh

24060

Oncology & Hematology Associates of SW Virginia, Blacksburg

29414

Charleston Hematology Oncology Associates, Charleston

30307

Emory University, Atlanta

32503

Woodlands Medical Specialists, PA, Pensacola

32763

Mid Florida Hematology and Oncology Centers, Orange City

33612

Moffitt Cancer Center, Tampa

36604

University of Alabama, Mitchell Cancer Institute, Mobile

37203

Sarah Cannon Research Institute, Nashville

38138

West Clinic, Germantown

45242

Oncology Hematology Care Inc., Cincinnati

48109

University of Michigan, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

63110

Washington University, St Louis

68130

Nebraska Cancer Specialists, Omaha

75702

Texas Oncology-Tyler, Tyler

77024

Texas Oncology-Memorial City, Houston

80045

University of Colorado, Aurora

80218

Rocky Mountain Cancer Centers, Denver

97213

Providence Cancer Center, Portland

07652

The Valley Hospital, Luckow Pavilion, Paramus

00927

Fundacion De Investigacion, Hematology/Oncology, San Juan

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Aeglea Biotherapeutics

INDUSTRY

NCT03371979 - Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter